Investigating how TET inhibition can improve cancer immunotherapy
Exploring the potential of TET inhibition in cancer immunotherapy
['FUNDING_R01'] · LA JOLLA INSTITUTE FOR IMMUNOLOGY · NIH-10880362
This study is looking at a new way to make cancer treatments work better by helping your immune cells fight tumors more effectively, especially for those with solid tumors, so that more patients can experience complete recovery.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | LA JOLLA INSTITUTE FOR IMMUNOLOGY (nih funded) |
| Locations | 1 site (LA JOLLA, UNITED STATES) |
| Trial ID | NIH-10880362 on ClinicalTrials.gov |
What this research studies
This research explores a novel approach to enhance cancer immunotherapy by inhibiting TET enzymes, which play a role in DNA demethylation. The study aims to improve the effectiveness of CAR T cells, particularly against solid tumors, by overcoming the exhaustion that these immune cells experience. By combining this strategy with existing therapies, the research seeks to increase the number of patients who achieve complete remission from their cancers. Patients may benefit from a more effective treatment option that harnesses their immune system to fight tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with solid tumors who have not responded well to existing immunotherapies.
Not a fit: Patients with hematological cancers that are effectively treated with current CAR T cell therapies may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve patient outcomes and increase remission rates.
How similar studies have performed: While the approach of TET inhibition in cancer immunotherapy is relatively novel, similar strategies targeting immune cell exhaustion have shown promise in other studies.
Where this research is happening
LA JOLLA, UNITED STATES
- LA JOLLA INSTITUTE FOR IMMUNOLOGY — LA JOLLA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: RAO, ANJANA — LA JOLLA INSTITUTE FOR IMMUNOLOGY
- Study coordinator: RAO, ANJANA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.